Sefaxersen (RO7434656)

Phase 3Small molecule

Sefaxersen (RO7434656) is one of 43 small molecule programs targeting Myotonic Dystrophy Type 1. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic Dystrophy Type 1Active, not recruiting

NephropathyActive, not recruiting

Myotonic Dystrophy Type 1Phase 2

Active, not recruiting

NephropathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

131 competitors in Nephropathy

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Phase 3

7 2

Zemplar

AbbVie

Phase 3

1 3

Simulect

Novartis

Phase 3

1 4

Ultomiris

AstraZeneca

Phase 3

—5

Acetadote

AArbor Pharmaceuticals, Inc.

Phase 3

3 6

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

1 7

Campath

GGenzyme, a Sanofi Company

Phase 3

1 8

Aurlumyn

BBTG International Inc.

Phase 3

1 9

Epoetin Beta

Roche

Phase 3

1 10

Povetacicept

Vertex Pharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

Nephropathy

NCT05797610

Clinical

Trials by Indication[1]

Nephropathy1 trial

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Recruiting· Roche logo

Roche·Phase 3·NCT05797610·428 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sefaxersen (RO7434656). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sefaxersen (RO7434656) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sefaxersen (RO7434656). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Sefaxersen (RO7434656)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Nephropathy1 trial

References

Drug Info

Quick Facts

Related News